XML 44 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events - Acquisition of Zavante (Details) - Subsequent Event - Zavante Therapeutics
$ in Millions
Jul. 23, 2018
USD ($)
shares
Subsequent Events  
Percentage of entity shares held by subsidiary 19.90%
Maximum  
Subsequent Events  
Contingent consideration payment $ 97.5
Approval Milestone Payment  
Subsequent Events  
Contingent consideration payment 25.0
Net Sales Milestone Payments  
Subsequent Events  
Contingent consideration payment $ 72.5
Upfront Shares  
Subsequent Events  
Business acquisition, ordinary shares issued or issuable | shares 7,336,906
Holdback Shares, as a percentage of Upfront Shares 10.00%
Holdback Shares  
Subsequent Events  
Business acquisition, ordinary shares issued or issuable | shares 815,186